Main Article Content

Lactate dehydrogenase (LDH) and evaluation of response to breast cancer chemotherapy


Fabienne Marie Soudre
Alice Kiba
Arnaud Kouraogo
Raoul Karfo
Aboubacar Bambara
Arsène Kagambega
Elie Kabre
Jean Sakande
Jacques Simpore

Abstract

Breast cancer is the leading cause of cancer death in women worldwide. The aim of this study was to determine the value of post-therapy serum LDH in assessing response at the completion of chemotherapy in breast cancer patients. This was a prospective cross-sectional study with data collection from May 2019 to November 2020, at the University Hospital of Bogodogo and at the SANDOF Polyclinic. We performed the LDH assay on serum from patients at the end of breast cancer chemotherapy who were at least 18 years old. Thirty (30) patients were included, with a mean age of 47.47 ± 2.10 years. Based on RECIST criteria, 46.67% had a successful response to chemotherapy, while 53.33% had a poor response. The mean post-therapy serum LDH was 256.15±25.99 U/L and 46.67% of patients had elevated serum LDH. Mean serum LDH was significantly higher in patients with a personal history of breast cancer (p=0.0198), increased CA 15-3 (p=0.0489) and poor response to chemotherapy (p=0.0291). Serum LDH was significantly higher in patients with a poor response to chemotherapy. Further studies are required to establish a more reliable correlation between serum LDH levels and response to breast cancer chemotherapy.


Journal Identifiers


eISSN: 1997-342X
print ISSN: 1991-8631